Zepbound with other medicines and health conditions

Zepbound or Mounjaro: one drug, two labels

Zepbound contains tirzepatide, and Lilly says it should not be used with other tirzepatide products ^[4]. Mounjaro is the other tirzepatide product. Its label covers blood sugar control in adults and children 10 and older with type 2 diabetes, and lowering the risk of heart attack, stroke and cardiovascular death in high-risk adults with type 2 diabetes ^[2]. Zepbound's label covers weight reduction and sleep apnea ^[1]. So if diabetes treatment is the goal, Mounjaro is the labeled brand; see Mounjaro vs Zepbound and Mounjaro.

The label split shows up in coverage too. Medicare's GLP-1 Bridge for weight drugs excludes people with type 2 diabetes, who may get GLP-1 coverage through their regular Part D plan instead ^[5]. Our sources contain no label language on type 1 diabetes for Zepbound; anyone with type 1 diabetes should ask their endocrinologist.

Does Zepbound lower A1C?

Yes, in its trials. In Study 2, adults with type 2 diabetes started with an average HbA1c of 8.0% to 8.1%. At 72 weeks it fell 2.1 points on 10 mg and 15 mg vs 0.5 on placebo. In Study 1, adults without diabetes started at 5.6% and fell 0.4 points vs 0.1 ^[3]. New-onset diabetes is not among the label's warnings ^[3]. More trial data are on Zepbound results.

Insulin, sulfonylureas and low blood sugar

This is the interaction with the clearest numbers. In the diabetes trial, low blood sugar under 54 mg/dL occurred in 4.2% on Zepbound vs 1.3% on placebo, and in 10.3% of people also taking a sulfonylurea ^[3]. The label tells prescribers to consider lowering insulin or sulfonylurea doses when Zepbound starts ^[3]. The Medication Guide asks you to tell your provider if you take either ^[6].

Thyroid conditions

The boxed warning covers thyroid C-cell tumors in rats; it is unknown whether Zepbound causes them in people. Zepbound must not be used with a personal or family history of medullary thyroid carcinoma or MEN 2. The label says routine calcitonin tests or thyroid ultrasounds are of uncertain value for catching these tumors ^[3]. Report a neck lump, trouble swallowing, shortness of breath or lasting hoarseness ^[3].

Our sources do not address hypothyroidism, hyperthyroidism or thyroid hormone levels for Zepbound. They do flag thyroid pills indirectly: Zepbound slows stomach emptying, and the label advises monitoring oral drugs that need precise blood levels to work ^[3]. For comparison, the Wegovy label reports that its tablet raised levothyroxine exposure by 33% ^[7]; the Zepbound label in our research gives no such figure. Ask your prescriber whether your thyroid dose needs checking.

Pain relievers and other medicines

• Ibuprofen and other pain relievers: not named in the Zepbound drug interaction section ^[3]. The label does warn that fluid loss from vomiting or diarrhea can cause acute kidney injury ^[3], so ask your pharmacist.
• Birth control pills: switch to a non-oral method or add a barrier method for 4 weeks after starting Zepbound ^[3] and, per the tirzepatide labels, after each dose increase ^[2].
• Other GLP-1 or tirzepatide drugs: not recommended with Zepbound ^[1].

Kidneys, liver, pregnancy and surgery

No Zepbound dose change is recommended for kidney or liver impairment ^[3]. Zepbound should be stopped once pregnancy is recognized ^[3]. Before any surgery or sedation, tell the team you take it, because aspiration has been reported under anesthesia ^[3]. The molecule-level page, tirzepatide interactions, covers blood pressure, breastfeeding and fertility in more depth.

Side effects in full are on Zepbound side effects. Coverage for diabetes vs weight is on Zepbound insurance and GLP-1 Medicare coverage.